Abstract: The present invention provides compounds of the formula (I): ##STR1## or salts, esters or amide derivatives thereof, wherein R.sub.1 is --CO.sub.2 H, --CH.dbd.CH--CO.sub.2 H, --(CH.sub.2).sub.n CO.sub.2 H, or --O--(CH.sub.2).sub.n CO.sub.2 H (n=1 to 4); R.sub.2 is C.sub.1.varies. alkyl or benzyl which is optionally substituted by a C.sub.1-4 alkyl group or groups; R.sub.3 is C.sub.1-4 alkoxy, C.sub.1-4 alkyl or halogen. Also provided are pharmaceutical formulations containing the compounds of the formula (I) and methods for the preparation of the compounds. The above mentioned compounds have antihistaminic activity.

Abstract: The invention provides compounds of the formula (I) ##STR1## or salts, esters, or amides or other protected forms thereof; wherein R.sub.1 is a C.sub.1-7 bivalent aliphatic hydrocarbon group or a single bond;R.sub.2 and R.sub.3 are the same or different and are each hydrogen, C.sub.1-4 alkyl or taken together with the nitrogen comprise a nitrogen-containing heterocyclic ring having four to six ring members;X is --N.dbd. or --CH.dbd.;A and B each represent hydrogen atoms or --CA--CB-- represents --C.dbd.C--; and D is an acidic group other than a carboxylic acid group.Also provided are pharmaceutical compositions of compounds of the formula (I), methods for the preparation of the compounds and intermediates in their preparation.The compounds of the formula (I) have antihistamic activity.

Abstract: This disclosure describes compounds of Formula I. ##STR1## (including their pharmaceutically acceptable salts and esters) which have potent antihistamine activity which are substantially free from sedative effects.

Abstract: This disclosure describes a compound of Formula I ##STR1## (including its pharmaceutically acceptable salts and esters) which has potent antihistamine activity which is substantially free from sedative effects and which has little or no anticholinergic effects.

Abstract: This disclosure describes a compound of Formula 1 ##STR1## (including its pharmaceutically acceptable salts and esters) which has potent antihistamine activity which is substantially free from sedative effects and which has little or no anticholinergic effects.

Abstract: The compound 2-[10-(2-Dimethylaminopropyl)-2-phenothiazinyl]-2-methylpropionic acid or a pharmaceutically acceptable salt thereof. The compound and salt are useful as antihistamines.

Abstract: This disclosure describes compounds of formula I. ##STR1## wherein X is Cl or Br (including their pharmaceutically acceptable salts and esters) which have potent antihistamine activity and which are substantially free from sedative effects.

Abstract: The invention provides a compound of the formula (I): ##STR1## or a salt, ester or amide thereof; wherein R.sub.1 is hydrogen or C.sub.1-4 alkyl and R.sub.2 is C.sub.1-4 alkyl substituted by a group R.sub.3 CO.sub.2 H or R.sub.1 and R.sub.2 taken together with the nitrogen comprise a nitrogen-containing heterocyclic ring having four to six ring members substituted by a group R.sub.3 CO.sub.2 H, wherein R.sub.3 is a C.sub.1-7 aliphatic hydrocarbon group or a single bond;R.sub.4 is hydrogen, halogen, hydroxy, cyano, C.sub.1-4 acyloxy, C.sub.1-4 alkoxy or C.sub.1-4 alkyl optionally substituted by one to three halogen atoms;X is --N.dbd. or --CH.dbd.; andA and B each represent hydrogen atoms or --CA--CB-- represents --C.dbd.C--.The invention also provides a method for the preparation of compounds of the formula (I), novel chemical intermediates in their preparation and pharmaceutical formulations. Compounds of the formula (I) have antihistaminic activity.

Abstract: The present invention provides a compound of the formula (I): ##STR1## or a salt, ester or amide thereof; wherein R.sub.1 is --COOH, --CH.dbd.CH--COOH, --CH.sub.2 COOH, or (CH.sub.2).sub.2 COOH. R.sub.2 is alkoxy (1-4 carbons), alkyl (1-4 carbons), hydrogen, or halogen. R.sub.3 and R.sub.4 may be the same or different and can be hydrogen, or lower alkyl(1-4 carbons) or NR.sub.3 R.sub.4 is pyrrolidino.Also disclosed are methods for the preparation of the above compounds and pharmaceutical formulations containing them.The above compounds have antihistaminic activity.

Abstract: This disclosure describes a compound of Formula I ##STR1## (including its pharmaceutically acceptable salts and esters) which has potent antihistamine activity which is substantially free from sedative effects and which has little or no anticholinergic effects.

Abstract: This disclosure describes compounds of Formula I. ##STR1## (including their pharmaceutically acceptable salts and esters) which have potent antihistamine activity which are substantially free from sedative effects.

Abstract: This disclosure describes compounds of Formula I. ##STR1## (including their pharmaceutically acceptable salts and esters) which have potent antihistamine activity which are substantially free from sedative effects.

Abstract: This disclosure describes a compound of Formula I ##STR1## (including its pharmaceutically acceptable salts and esters) which has potent antihistamine activity which is substantially free from sedative effects and which has little or no anticholinergic effects.

Abstract: A radioimmunoassay proceedure has been discovered for bupropion [(.+-.)-2-t-butylamino-3-chloropropiophenone], an antidepressant compound, in biological fluids. Novel compounds of formula ##STR1## wherein either R.sub.2 is oxygen and R.sub.1 is (CH.sub.2).sub.n --O--(CO).sub.m --(CH.sub.2).sub.p --COOH where n is an integer from 0 to 5, m is 0 or 1, and p is an integer from 1 to 4; or R.sub.1 is hydrogen and R.sub.2 is N--O--(CH.sub.2).sub.q --COOH where Q is an integer from 1 to 3, and novel methods of making them and novel intermediates useful therein are disclosed. Novel immunogens for raising bupropion specific antisera, and novel methods of making them are disclosed comprising conjugates of the novel compounds and suitable carrier material. The drug is added to the antisera together with novel radiolabeled competitor of formula ##STR2## wherein R' is a suitable radioisotope as described above and R.sub.3 is hydrogen, R.sub.4 is Cl, and R.sub.5 is oxygen, orR' is hydrogen and either(a) R.sub.3 is H and R.

Abstract: A radioimmunoassay procedure has been discovered for bupropion [(.+-.)-2-t-butylamino-3-chloropropiophenone], an antidepressant compound, in biological fluids. Novel compounds of formula ##STR1## wherein either R.sub.2 is oxygen and R.sub.1 is (CH.sub.2).sub.n --O--(CO).sub.m --(CH.sub.2).sub.p --COOH where n is an integer from 0 to 5, m is 0 or 1, and p is an integer from 1 to 4; or R.sub.1 is hydrogen and R.sub.2 is N--O--(CH.sub.2).sub.q --COOH where q is an integer from 1 to 3, and novel methods of making them and novel intermediates useful therein are disclosed. Novel immunogens for raising bupropion specific antisera, and novel methods of making them are disclosed comprising conjugates of the novel compounds and suitable carrier material. The drug is added to the antisera together with novel radiolabeled competitor of formula ##STR2## wherein R' is a suitable radioisotope as described above and R.sub.3 is hydrogen, R.sub.4 is Cl, and R.sub.5 is oxygen, orR' is hydrogen and either(a) R.sub.3 is H and R.

Abstract: A radioimmunoassay procedure has been discovered for bupropion [(.+-.)-2-t-butylamino-3-chloropropiophenone], an antidepressant compound, in biological fluids. Novel compounds of formula ##STR1## wherein either R.sub.2 is oxygen and R.sub.1 is (CH.sub.2).sub.n -O-(CO).sub.m -(CH.sub.2).sub.p -COOH where n is an integer from 0 to 5, m is 0 or 1, and p is an integer from 1 to 4; or R.sub.1 is hydrogen and R.sub.2 is N-O-(CH.sub.2).sub.q -COOH where q is an integer from 1 to 3, and novel methods of making them and novel intermediates useful therein are disclosed. Novel immunogens for raising bupropion specific antisera, and novel methods of making them are disclosed comprising conjugates of the novel compounds and suitable carrier material. The drug is added to the antisera together with novel radiolabeled competitor of formula ##STR2## wherein R' is a suitable radioisotope as described above and R.sub.3 is hydrogen, R.sub.4 is Cl, and R.sub.5 is oxygen, or R' is hydrogen and either(a) R.sub.3 is H and R.sub.